CRNXCrinetics Pharmaceuticals Inc
CRNX
Crinetics Pharmaceuticals Inc1,456
Mkt Cap
$3.72BVolume
786.0052W High
$57.9952W Low
$24.10PE Ratio
-7.19CRNX Fundamentals
Price
$35.57Prev Close
$35.82Open
$35.8250D MA
$45.69Beta
1.17Avg. Volume
1MEPS (Annual)
-$4.95P/B
3.43Rev/Employee
$12,956.23$3,399.01
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
JPMorgan Chase & Co. lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 279.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,258,722 shares of the company's stock after acquiring an additional 926,765 share...
MarketBeat·2d ago
Richard Scott Struthers Sells 21,981 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 21,981 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief...
MarketBeat·4d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 21,981 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total value of $821,429.97. Following the sale, the...
MarketBeat·5d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Stephen Betz Sells 10,612 Shares
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen Betz sold 10,612 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $396,570.44. Following the completion of the...
MarketBeat·5d ago
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) COO Sells 9,911 Shares of Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) COO Jeff Knight sold 9,911 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $370,374.07. Following the completion of the sale, the chief...
MarketBeat·5d ago
First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
First Light Asset Management LLC increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.0% in the 3rd quarter, according to its most recent filing with...
MarketBeat·7d ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Sells $180,750.00 in Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) Director Coelho Rogerio Vivaldi sold 5,000 shares of the business's stock in a transaction on Thursday, March 12th. The stock was sold...
MarketBeat·9d ago
Coelho Rogerio Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) Director Coelho Rogerio Vivaldi sold 5,000 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at...
MarketBeat·9d ago
Pier Capital LLC Has $3.12 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX
Pier Capital LLC trimmed its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 47.4% in the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·10d ago
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf.
Executives from Crinetics Pharmaceuticals (NASDAQ:CRNX) used an investor discussion at TD Cowen's 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched...
MarketBeat·15d ago
<
1
2
...
>